Business
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2
About this update from Immunitybio, Inc.
[{"type":"text","content":"\nStudy shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells \n\n\nStudy results suggest this next-generation human adenovirus 5 (hAd5) vaccine, which delivers both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, stimulates memory CD4+ and CD8+ T-cells, both of which may be critical for clearing virus infected cells.\n\n\nTogether with earlier studies in pre-clinical models, which demonstrate the vaccine’s immunogenicity, these findings support the further use of this vaccine as a therapeutic in newly infected patients to limit lateral transmission of the disease.\n\n\nT-cell response may provide long-term immunity and mitigate waning short-lived antibodies against the coronavirus.\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. a privately-held, clinical-stage immunotherapy company, today announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which shows memory T-cell recall from patients previously infected with SARS-CoV-2 virus. The ability to stimulate SARS-CoV 2 specific T-cells, which recognize the N and S proteins, is a crucial part of the novel design of ImmunityBio’s vaccine candidate. The antibody- and T cell-based vaccine seeks both to provide protection for the uninfected population and also the potential to clear virally infected cells in infected subjects. It is unclear how long antibodies may provide protection. With the production of both antibodies and T cells, the potential exists for long-term, durable immunity. The results of this study were published in medRxiv (“Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2”).\n\nImmunityBio’s vaccine candidate targets both the spike (S) and nucleocapsid (N) proteins (hAd5 S + N) of SARS-CoV-2 to activate a multi-pronged attack by the immune system. This is distinct from most vaccine candidates currently in late-stage clinical trials, which target S alone. Recent reports suggest that antibodies to S may be vulnerable to reduced effectiveness becau...